—Older age, presence of scoliosis, and other factors were associated with lower predicted forced vital capacity in patients with Duchenne muscular dystrophy using non-invasive ventilation. Individuals ...

A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...

SAN FRANCISCO — A molecular variant of an older, hard-to-tolerate antifibrotic agent showed promise for reducing decline in forced vital capacity (FVC) over 26 weeks among patients with idiopathic ...

Better lung function, expressed as higher forced vital capacity (FVC), is associated with a reduced risk for the onset of heart disease, diabetes, and stroke over a follow-up period of approximately ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Following use of race-neutral lung function equations, African American and Latino pediatric ...

For initial treatment of symptomatic pulmonary sarcoidosis, methotrexate appeared to work as well as prednisone over 24 weeks, the randomized PREDMETH trial showed. Mean change from baseline in the ...

The mean change in the percentage of FVC from baseline to week 24 was 6.75 and 6.11 percentage points in the prednisone and methotrexate groups, respectively. HealthDay News — For patients with ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.